Genkyotex announced the presentation of additional data from the Phase 2 trial of setanaxib in primary biliary cholangitis (PBC). These latest results show that in patients with elevated liver stiffness (=9.6 kPa corresponding to the histological fibrosis stage = F3), setanaxib reduced type III collagen formation and induced type III collagen degradation, resulting in a net reduction of collagen accumulation. Collagen III is the main collagen type secreted by activated myofibroblasts. As a reminder, the key finding of the PBC Phase 2 trial was the rapid reduction in liver stiffness (-20.9% for setanaxib vs +4% for placebo, p<0.05) in patients with elevated liver stiffness (= 9.6 kPa), i.e. those with advanced liver fibrosis. Fibrosis progression is primarily caused by increased collagen III formation (measured by PRO-C3, the pro-peptide of type III collagen) and insufficient collagen III degradation (measured by C3M). The latest results show that in the Phase 2 PBC trial, patients with elevated liver stiffness at baseline had increased PRO-C3 levels and PRO-C3/C3M ratios. After 24 weeks of treatment, setanaxib reduced PRO-C3 (collagen III formation), increased C3M (collagen III degradation) levels, and reduced the PRO-C3/C3M ratio indicating reduced collagen III net accumulation. Setanaxib also increased serum levels of C4M (p<0.05), a marker of type IV collagen degradation. Genkyotex will submit this new data for presentation at key international liver conferences.